07:19 AM EDT, 03/26/2026 (MT Newswires) -- MapLight Therapeutics ( MPLT ) reported a Q4 net loss Thursday of $2.47 per diluted share, narrower than loss of $27.95 a year earlier.

Two analysts polled by FactSet expected a loss of $0.78.

As of Dec. 31, the company said it had $453.1 million in cash and cash equivalents on hand, and expected it could fund operations through 2027.

The company's shares were down 7.5% in premarket activity on Thursday.